The latest Investing Matters Podcast episode featuring financial educator and author Jared Dillian has been released. Listen here.
Yes, everything looks positive here, patience needed but still a buy and hold for me at these levels
So, why is it so cheap? I hear you all say it should be £1 plus, but it never gets past the 70s despite positive sounding RNS's...I've traded this a few times as it appears to be stuck in A trading channel. I want to go long here but I end up selling. Why? Is it purely market ignorance?
The market has either not placed great value in the RNS or not noticed it and currently only has eyes for other more in your face stocks such as Opti....or we have misunderstood the RNS and placed too great a value in it. However, I can't see how this quote from the RNS points can't augur well for OXP "The body of data shows this is a versatile and flexible technology that can allow major brand owners to create and sustain competitive advantage in the large and growing ibuprofen market"....a market worth globally $4bn. OXP are talking to the big global pharmas. Surely only a matter of time?
You need to be careful reading too much into red numbers - quite a few buys over the last few days been just below mid and shown red, and again this morning. However, no denying there are some sells, but small volumes. Point about Woodford is correct - he invests in many companies and his fund returns about 15% average. Obviously, much of that is through many large companies delivering steady growth, which he looks to boost by trying to find a few multibagger small caps. Not everything he touches multibags that's for sure. No signs yet of him reducing here, and I see no reason why he would given the reported progress being made.
Whats does EOM mean Impervious? But I agree, around 80p and under is a good buy in price. Been quiet here for a while, then board is beefed up and directors buy (before entering a closed period?), heavy government interest and a possible £1.3bn fund to tap into next year at some point, Neil Murray sharing a platform today with the govt top man Jim O'Neill. I could be way off beam but I'm getting a feeling things are stirring and 2016 could be a big year for this company.
Perhaps we can all just agree that an equity raising in the foreseeable future is most unlikely. Personally, I looked at the cash position and concluded that given yesterday's news, it is more likely some commercial deal will be reached on OXPzero ibuprofen before the cash runs out, so I'm happy with where we are....but I'm no expert on the ins and outs of the pharmaceutical process.
Been watching this since launch and cursed myself for watching when it went to 125p. I think it's fallen purely on no news syndrome. Finances and product progress look good. Not many shares in issue and only 25% free float. Nearly jumped in at 77p a few days ago, but the bod strengthening yesterday and director buys have convinced me to take a small position this morning while sp is still at discount to original placing price. It looks to me like they're gearing up for progress. High risk this but exceptionally high profile and high value products which if successful will generate tremendous rewards.
I agree Woodford is no cast iron guarantee (look at UTW currently), but he's a good man to have on your side, if only as he almost acts as an unofficial NED. The Naproxen score was what took us down and I think is now accounted for in the sp - I agree that they should be able to reformulate and prove up to commercialisation status next year. Been able to buy below mid since yesterday afternoon so don't be fooled by the red numbers....only trades close to bid price are actually sells.
Yes, I interpreted the RNS as all good and thought it might provoke a slightly better market response. Anyone see anything to be cautious about in the data? Seems to me OXP is in a better place than when the sp went to 13p in the summer, but what do I know? Hopefully some more ii's will be tempted now, but as long as Woodford keeps liking what he sees, then I remain in.
I always like reading the words "at an advanced stage" , especially when combined with the word "commercialisation". I also like "We continue making great progress with other key NSAIDs, namely OXPzeroTM Naproxen, OXPzeroTM Diclofenac and OXPzeroTM Aspirin and also evaluating further targets". In all it appears to be a very upbeat RNS.
Shorts are undoubtedly exiting, but for every short reduction of 1% (ie from 6.8% to 5.8%), the sp drops 10%....so 30p may be hit? I'm waiting a tad longer for a re-entry just in case, and only because I think a bottom may have been reached and a bounce could happen... I will sell quickly if December numbers are anything other than above average.. this is all guesswork as no firm indications being issued by the company
Like I said GS, good timing... not profitable at all at the minute mainly as I don't hold much. Liquidated most of my AIM stuff to stay in cash about 5 months ago and been watching ever since...unfortunately much of that cash was snapped up by my wife for a new car and a summer house so I have a much diminished war chest to take advantage of any unexpected bargains. Did have a small amount in here at 66 to trade the run up prior to results but jumped out at 72. Have decided short term trades probably better than holding long given the markets and my general distrust of AIM. Looks like I missed a trade here today, but I'm still scarred by QPP and just don't have the confidence to buy in following such a drop until I know what's going on. Not been in ET's lot for ages nor will I be until they can show they're going somewhere - just treading water at the minute from what I can see. ATB
Perhaps it is something worse then...certainly some big sells by people who should in theory understand the model. Some late morning rumour has spooked the market, either it's true or we should expect a company RNS surely? A 20% loss in company value in an hour is noteworthy.